Brookline Capital initiates Candel Therapeutics stock with Buy rating, $25 target – RP Digital

Business

Brookline Capital initiates Candel Therapeutics stock with Buy rating, $25 target

July 9, 20251 min0

Brookline Capital initiates Candel Therapeutics stock with Buy rating, $25 target

Source link

rpdigital

Leave a Reply Cancel reply

Related Articles

BancFirst declares quarterly dividend and trust interest payment

rpdigitalAugust 28, 20250

Jefferies raises Ollie's Bargain Outlet stock price target to $135 on strong growth

rpdigitalAugust 28, 20250